Lourdes F. Calvo - Publications

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 25, 2025

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Journal: The oncologist

Published: May 07, 2025

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2025

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.

Journal: International journal of cancer

Published: September 18, 2024

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.

Journal: The oncologist

Published: August 28, 2024

Progress and challenges in valorisation of biomass waste from ornamental trees pruning through pyrolysis processes. Prospects in the bioenergy sector.

Journal: Environmental research

Published: October 31, 2023

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 27, 2023